東誠藥業(002675.SZ):認購APRINOIA Therapeutics Inc.股權交割完成
格隆匯6月8日丨東誠藥業(002675.SZ)公佈,此前披露,2021年2月5日,公司與APRINOIA Therapeutics Inc. (“目標公司”)簽署了《C系列優先股認購協議》,以現金1807.29萬美元認購目標公司增發的1348.72萬股C系列優先股,佔此次增發股份的86%;同時在本輪投資交割前,按照公司可接受的條件購買其原有股東部分股權,數量不低於385.43萬股。
截至2021年6月8日,此次交易的各方均已經根據相關約定完成了其在交割前應盡的義務與工作,此次對外投資標的資產的交割手續已履行完畢,待目標公司C輪股份和員工期權發放完成後,公司在目標公司的持股比例將為16%。目前,公司正按照既定計劃有序開展各項後續工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.